Our Pipeline
Our clinical development programs have the potential to address numerous immune-mediated diseases that impact large patient populations with limited therapeutic options.
STAGE OF DEVELOPMENT
Indication(s)
Pre-Clinical
IND-Enabling
Phase 1
Phase 2
Phase 3
Candidate
Budoprutug SC
Anti-CD19
Indications
Autoimmune Disease
IND-Enabling
*Subject to investigational new drug application clearance
Scientific Approach
We develop differentiated, best-in-class monoclonalantibodies for immune-mediated diseases.
Pipeline
We have the potential to address numerous immune-mediated diseases that impact large patient populations with limited therapeutic options.